- Home
- ARQT vs XENE Comparison
ARQT vs XENE Comparison
Compare ARQT & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | XENE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 5.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARQT | XENE |
|---|---|---|
| Price | $23.22 | $55.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $34.00 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 909.3K | 770.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $376,072,000.00 | $311,000.00 |
| Revenue This Year | $34.85 | N/A |
| Revenue Next Year | $29.39 | $2,496.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $12.42 | $28.19 |
| 52 Week High | $31.77 | $62.91 |
Technical Indicators
Market Signals| Indicator | ARQT | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 51.36 |
| Support Level | $22.56 | $52.55 |
| Resistance Level | $23.46 | $56.66 |
| Average True Range (ATR) | 0.92 | 1.86 |
| MACD | -0.10 | -0.59 |
| Stochastic Oscillator | 35.33 | 40.58 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.